Navigation Links
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Date:9/5/2007

- Phase 2 Median Overall Survival Confirmed and Extended at the 12th World

Conference on Lung Cancer in Seoul -

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC). Picoplatin is currently being studied in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is evaluating overall survival as the primary endpoint and is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Yesterday, Poniard presented updated data from its Phase 2 SCLC trial at the 12th World Conference on Lung Cancer in Seoul, which confirmed and extended a median overall survival of 27 weeks (based on an analysis of 63 patients), which compares favorably to a median survival of approximately 17 to 22 weeks for patients who receive other second-line chemotherapy according to the 2007 National Comprehensive Cancer Network practice guidelines.

"Our receipt of fast track designation is the result of our ongoing communications with the FDA, and has the potential to accelerate the development of picoplatin for the treatment of small cell lung cancer, a difficult-to-treat disease, and a patient population with very limited treatment options," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We are focused on executing our ongoing Phase 3 SPEAR trial to facilitate the expeditious filing of a New Drug Application
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... May 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, ... Annual dbAccess Health Care Conference in Boston.   ... 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.  The ... Company,s website at http://www.neurocrine.com . If ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:5/23/2013)... is associated with poor outcomes in hospitalized patients, and ... is a common practice in hospitals. But the recent ... shows harms associated with the use of IIT, according ... Committee in a new evidence-based paper published today online ... , "Clinicians caring for hospitalized patients must keep the ...
(Date:5/23/2013)... 2013 Internationally recognized as one of ... for over 29 years, Coach Nick Saviano’s ... WTA players, Grand Slam winners, World #1’s; Junior Wimbledon, ... USTA National Junior Champions, 8 Foreign National Junior Champions ... Cup, Orange Bowl and Eddie Herr winners - and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... UNITED KINGDOM (PRWEB) May 24, 2013 ... by A.L. Hodkin, A.F. Huxley and B. Katz in ... to account for the role of sodium and potassium ... electrophysiological techniques and the data acquisition techniques have known ... Yves Pichon wants to give an account of ...
(Date:5/23/2013)... In his pulse-quickening novel, “The AIDS Covenant” (published by AuthorHouse), ... government?” , In the “The AIDS Covenant,” readers meet Dr. ... ’s Heathrow Airport. His American colleague, Alan Milner of BAYMED ... arrive at his Sierra Nevada ski-lodge. , ... the government’s report. When Alan learns that Owen was killed ...
Breaking Medicine News(10 mins):Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:New Book “The AIDS Covenant” by Roy Harris Delivers Intriguing, Captivating Story 2
... The National Commander of the Disabled American Veterans begins ... support for budget reform legislation to ensure sufficient, timely ... is urging them to reject a contentious proposal that ... conditions from the government,s side of the ledger to ...
... cranberriesand not the acidity of cranberry juice, as previously ... line the urinary tract, as documented in a report ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ... www.liebertpub.com/jmf , Urinary tract infections (UTIs) burden ...
... March 9 Quest Diagnostics Incorporated (NYSE: ... information and services, announced that it is scheduled to ... on Tuesday, March 10, 2009. The Quest Diagnostics ... Time.During the conference, the company will reaffirm its 2009 ...
... Sport Beans and Nike Motivate College Students to Complete ... SpringNEW YORK, March 9 American Collegiate Intramural Sports ... corporate sponsors are joining together to launch ACIS Fitness ... college marketing platform is aimed at motivating the 2.7 ...
... Japanese scientists will arrive at the University of Houston ... that promises to deliver more comprehensive and accurate insights ... of current technologies. , In April, Mikio Kubota of ... join the research team at UH,s Biomedical Imaging Lab. ...
... President Obama signed an executive order ... stem cell research, overturning limits on federal funding for ... President & CEO of Americans United for Life responded, ... past. Millions of dollars have been spent on ...
Cached Medicine News:Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference 2Health News:ACIS Fitness Challenges Launch Across 200 Colleges Nationwide 2Health News:UH research team developing new noninvasive brain-mapping technology 2Health News:UH research team developing new noninvasive brain-mapping technology 3Health News:UH research team developing new noninvasive brain-mapping technology 4Health News:Americans United for Life: Obama Administration Stem Cell Policy an Anti-Life Waste of Tax Dollars 2
... tissue, mucous, and other body fluids -- ... as box joints and tubing -- while ... Original is strong enough for the toughest ... everyday. Prolong the life of your instruments ...
... MPD is the highly ... surgical instruments manually or with an ... enough to remove blood and organic ... cleaning. Use MPD to clean surgical ...
... Features you need for critical patients ... blood,pressures, a comprehensive calculations package and ... that you can transport with your ... frequently used functions which means ...
The ApexPro CH is operational within the WMTS. It offers operating performance, up to 240 WMTS channels, and up to 120 hours of battery life....
Medicine Products: